feat(data): Add initial structured sample datasets

data/approvals/sample-approval-1.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Amiodarone",
+  "indication": "Antiarrhythmic",
+  "approval_date": "2023-08-15",
+  "regulatory_body": "FDA",
+  "status": "Approved",
+  "notes": "Fast track approval due to critical need in arrhythmia management."
+}

data/approvals/sample-approval-2.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Taltz",
+  "indication": "Plaque Psoriasis",
+  "approval_date": "2016-03-22",
+  "regulatory_body": "EMA",
+  "status": "Approved",
+  "notes": "Biologic drug targeting IL-17A. Approved for moderate to severe cases."
+}

data/approvals/sample-approval-3.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Zocor",
+  "indication": "Hypercholesterolemia",
+  "approval_date": "1991-12-16",
+  "regulatory_body": "FDA",
+  "status": "Approved (Generic Available)",
+  "notes": "HMG-CoA reductase inhibitor (statin). Now widely used as a generic (Simvastatin)."
+}

data/pipeline/sample-pipeline-1.json

@@ -0,0 +1,8 @@
+{
+  "candidate_id": "OPRX-402",
+  "target_disease": "Infectious Disease",
+  "current_phase": "Phase II",
+  "start_date": "2023-05-10",
+  "expected_completion": "2025-11-01",
+  "notes": "Testing efficacy against multi-drug resistant bacterial strains."
+}

data/pipeline/sample-pipeline-2.json

@@ -0,0 +1,10 @@
+
+{
+  "candidate_id": "OPRX-510",
+  "target_disease": "Alzheimer's Disease",
+  "current_phase": "Phase I (Pre-IND)",
+  "start_date": "2024-01-25",
+  "expected_completion": "2026-06-30",
+  "notes": "Focus on early-stage amyloid plaque reduction and safety profile."
+}
+

data/pipeline/sample-pipeline-3.json

@@ -0,0 +1,10 @@
+
+{
+  "candidate_id": "OPRX-601",
+  "target_disease": "Type 2 Diabetes",
+  "current_phase": "Phase III (Recruiting)",
+  "start_date": "2022-09-01",
+  "expected_completion": "2024-12-31",
+  "notes": "Large multi-site international trial focusing on A1C reduction and cardiovascular outcomes."
+}
+

data/pricing/sample-pricing-1.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Amiodarone",
+  "unit_of_sale": "100mg tablet (bottle of 30)",
+  "wholesale_cost": 45.00,
+  "list_price": 99.99,
+  "manufacturer_rebate_rate": 0.15,
+  "notes": "Pricing reflects competitive landscape for generics."
+}

data/pricing/sample-pricing-2.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Taltz",
+  "unit_of_sale": "80mg/mL autoinjector (single unit)",
+  "wholesale_cost": 4500.00,
+  "list_price": 5800.00,
+  "manufacturer_rebate_rate": 0.28,
+  "notes": "Premium pricing due to specialized biologic status and limited competition."
+}

data/pricing/sample-pricing-3.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "OPRX-601",
+  "unit_of_sale": "200mg capsules (bottle of 60)",
+  "wholesale_cost": 150.00,
+  "list_price": 275.00,
+  "manufacturer_rebate_rate": 0.05,
+  "notes": "Planned launch price, pending Phase III success and competitive analysis."
+}

data/safety/sample-safety-1.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Amiodarone",
+  "report_id": "SA-2023-001",
+  "severity": "Moderate",
+  "adverse_event": "Thyroid Dysfunction",
+  "date_reported": "2024-01-20",
+  "actions_taken": "Issued updated black box warning."
+}

data/safety/sample-safety-2.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Taltz",
+  "report_id": "SA-2024-002",
+  "severity": "Mild",
+  "adverse_event": "Injection Site Reaction",
+  "date_reported": "2024-03-01",
+  "actions_taken": "Updated patient counseling materials regarding proper injection technique."
+}

data/safety/sample-safety-3.json

@@ -0,0 +1,8 @@
+{
+  "drug_name": "Zocor",
+  "report_id": "SA-2024-003",
+  "severity": "Severe",
+  "adverse_event": "Rhabdomyolysis",
+  "date_reported": "2024-04-10",
+  "actions_taken": "Restricted dosage for patients with renal impairment."
+}